片仔癀控股股东增持股份计划实施完毕公告

重要内容梳理

• 控股股东增持计划实施完毕：漳州市九龙江集团有限公司（控股股东）已完成对漳州片仔癀药业股份有限公司的增持计划。
• 增持金额达到计划下限：九龙江集团累计增持金额为49,999.76万元人民币，达到增持计划下限（30,000万元），但未超过上限（50,000万元）。
• 增持股份数量及比例：本次增持股份为3,171,311股，占公司总股本的0.53%。
• 控股股东持股比例提升：增持后九龙江集团合计持有公司股份310,693,954股，持股占比由50.97%提升至51.50%。
• 增持时间：增持计划实施期间为2026年2月1日至2026年7月31日，实际增持于2026年2月1日至4月30日完成。
• 增持方式：通过上海证券交易所集中竞价交易系统完成。
• 法律合规：本次增持符合《证券法》、《上市公司收购管理办法》及相关规范性文件要求，不触及要约收购，不会导致控股股东及实际控制人发生变化。
• 律师意见：北京市君致律师事务所出具法律意见书，认为增持主体资格合法，增持过程合规，且公司已履行信息披露义务。

对投资者的影响及需特别关注事项

• 控股股东增持动作通常被市场视为对公司前景的正面信号，表明管理层对公司价值的认可，有望提振市场信心，利好股价表现。
• 本次增持金额接近计划上限，显示控股股东对公司未来发展的高度看好。
• 增持后控股股东持股比例升至51.50%，进一步巩固控股地位，减少股权分散风险。
• 本次增持未引发要约收购，实际控制权未发生变化，避免控股权争夺风险。
• 公告已由律师事务所出具法律意见书验证，合规性充分保障。
• 增持计划已在规定时间内完成，后续不再有类似大额增持计划，投资者需关注公司后续经营及股东动态。

详细数据与增持过程

结论与投资建议

片仔癀控股股东九龙江集团完成了大额增持，彰显对公司未来发展的信心。增持提升了控股股东持股比例，有利于公司治理结构稳定，并对市场传递积极信号。投资者可密切关注公司后续经营业绩、控股股东动向及行业发展变化。

免责声明

本报道仅为信息披露解读，不构成任何投资建议。投资者应根据自身风险承受能力及市场情况，独立做出投资决策。公司公告内容及数据以官方公告为准。

Pien Tze Huang Major Shareholder’s Shareholding Increase Plan Completed

Key Highlights

• Completion of Shareholding Increase Plan: Zhangzhou Jiulongjiang Group Co., Ltd. (controlling shareholder) has completed its planned shareholding increase in Pien Tze Huang Pharmaceutical Co., Ltd.
• Amount Reached Lower Limit: Jiulongjiang Group increased its holdings by RMB 499.9976 million, meeting the minimum planned amount (RMB 300 million) but not exceeding the maximum (RMB 500 million).
• Shares Added & Proportion: 3,171,311 shares were purchased, accounting for 0.53% of the company’s total equity.
• Shareholding Proportion Raised: After the increase, Jiulongjiang Group holds 310,693,954 shares, and its stake rose from 50.97% to 51.50%.
• Timeline: The plan was set for February 1, 2026 to July 31, 2026; actual purchases occurred between February 1 and April 30, 2026.
• Method: Purchases were made via centralized bidding on the Shanghai Stock Exchange.
• Legal Compliance: The increase complies with the Securities Law, Administrative Measures for Acquisitions of Listed Companies, and related rules; it does not trigger a tender offer or change the controlling shareholder.
• Legal Opinion: Junzhi Law Firm issued a legal opinion confirming the legitimacy and compliance of the transaction and the fulfillment of disclosure obligations.

Investor Impact & Price Sensitive Points

• Shareholding increase by the controlling shareholder is typically viewed as a positive signal — it demonstrates confidence in the company’s prospects and may boost market sentiment and share price.
• The increase amount is close to the plan’s upper limit, showing strong optimism by the major shareholder.
• With shareholding rising to 51.50%, the controlling shareholder’s position is strengthened, reducing risk of shareholding dispersion.
• No tender offer is triggered, and there is no change in control — avoiding risks of control disputes.
• Legal verification ensures compliance and transparency.
• The plan is completed within the set timeframe; investors should watch future company operations and any further shareholder actions.

Detailed Data & Process

Conclusion & Investor Advice

The completion of a large-scale shareholding increase by Jiulongjiang Group highlights confidence in Pien Tze Huang’s future. The controlling shareholder’s stake is further consolidated, which is positive for corporate governance and market stability. Investors should keep an eye on subsequent business performance, shareholder moves, and sector developments.

Disclaimer

This report is for informational purposes only and does not constitute investment advice. Investors should make decisions independently based on their own risk tolerance and market analysis. Official company announcements and data prevail.

View 片仔癀 Historical chart here